Vaccine

Funding Opportunity: Detection of HIV for Self-Testing (R61/R33)

August 30, 2017

Announcement (FOA) Number PAR-17-471 

The purpose of this Funding Opportunity Announcement is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple dignostic tools that would be feasible for a self-testing platform to allow untrainded individuals to detect HIV. Interdisciplinary collaborations that...

Read more about Funding Opportunity: Detection of HIV for Self-Testing (R61/R33)
Forsyth

Postdoctoral Research Fellow Position Available at the Forsyth Institute, Cambridge, MA

August 10, 2017

A position for a postdoctoral research fellow is immediately available at the Forsyth Institute in Cambridge, Massachusetts             

We are very excited to embark on a NIH-sponsored project to develop a novel oral vaccine against HIV/AIDS. A postdoctoral fellow with a strong background in Immunology is sought for the careful planning and implementation of research projects involving assessments of mucosal/cellular immune responses to our novel HIV vaccine.

Please send submissions via...

Read more about Postdoctoral Research Fellow Position Available at the Forsyth Institute, Cambridge, MA

August 2017 Request for Proposals: CFAR Mucosal Immunology Group

August 4, 2017

CFAR Mucosal Immunology Group
Request for Proposals (August 2017)

This current Request for Proposals builds upon the accomplishments of the Mucosal Immunology Group (MIG) by extending scientific participation and support to members of the NIH Centers for AIDS Research (CFAR) network to create a CFAR Mucosal Immunology Group (CFAR-MIG). One of the primary goals of this group is to support innovative, method development studies by CFAR members. MIG awards are for one year with maximum funding per application of up to $100,000 Total Costs....

Read more about August 2017 Request for Proposals: CFAR Mucosal Immunology Group
Scott Dryden-Peterson

Botswana’s cautionary tale of the co-epidemic of HIV and cervical cancer

October 13, 2016

HIV infection increases mortality in African women with cervical cancer

“Botswana was the first country in Africa to provide comprehensive HIV treatment to its citizens and has one of the most effective antiretroviral treatment programs globally,” Scott Dryden-Peterson, MD, instructor of medicine at Harvard Medical School and associate physician at Brigham and Women’s Hospital, told HemOnc Today. “As such, trends in Botswana are indicative of what will happen in other heavily HIV affected countries that also now have good access...

Read more about Botswana’s cautionary tale of the co-epidemic of HIV and cervical cancer
BIDMC Research Team Presents Exciting New Results with Experimental HIV Vaccine in Monkeys

BIDMC Research Team Presents Exciting New Results with Experimental HIV Vaccine in Monkeys

July 13, 2015

An experimental HIV vaccine developed with Dr. Dan Barouch (HU CFAR Executive Committee member and Director of the HU CFAR Program in HIV Vaccines), his team of researchers at BIDMC, and Johnson & Johnson has protected 6 out of 12 monkeys against HIV. The exciting results, published in “Science,” are leading researchers to begin the first human trials with 400 volunteers in the U.S., Thailand, South Africa, Rwanda, and Uganda. Results are expected by next year, and the trials will ascertain whether or not the vaccine is safe and also creates an immune response. These will be the first...

Read more about BIDMC Research Team Presents Exciting New Results with Experimental HIV Vaccine in Monkeys

Pages